Cliff Asness's CGEM Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 281,483 shares of Cullinan Therapeutics, Inc. (CGEM) worth $2.91 M, representing 0.00% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CGEM, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 177,000 shares. Largest reduction occurred in Q3 2023, reducing 50,048 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Cullinan Therapeutics (CGEM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cullinan Therapeutics (CGEM) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +83,563 | Add 42.22% | 281,483 | $10.35 |
| Q3 2025 | +177,000 | Add 846.08% | 197,920 | $5.93 |
| Q2 2025 | +20,920 | New Buy | 20,920 | $7.53 |
| Q4 2023 | -21,774 | Sold Out | 0 | $0.00 |
| Q3 2023 | -50,048 | Reduce 69.68% | 21,774 | $9.05 |
| Q2 2023 | -16,470 | Reduce 18.65% | 71,822 | $10.76 |
| Q1 2023 | -23,068 | Reduce 20.71% | 88,292 | $10.23 |
| Q4 2022 | +2,958 | Add 2.73% | 111,360 | $10.55 |
| Q3 2022 | +87,493 | Add 418.45% | 108,402 | $12.82 |
| Q2 2022 | +20,909 | New Buy | 20,909 | $12.82 |
Cliff Asness's Cullinan Therapeutics Investment FAQs
Cliff Asness first purchased Cullinan Therapeutics, Inc. (CGEM) in Q2 2022, acquiring 20,909 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Cullinan Therapeutics, Inc. (CGEM) for 10 quarters since Q2 2022.
Cliff Asness's largest addition to Cullinan Therapeutics, Inc. (CGEM) was in Q3 2025, adding 197,920 shares worth $1.17 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 281,483 shares of Cullinan Therapeutics, Inc. (CGEM), valued at approximately $2.91 M.
As of the Q4 2025 filing, Cullinan Therapeutics, Inc. (CGEM) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Cullinan Therapeutics, Inc. (CGEM) was 281,483 shares, as reported at the end of Q4 2025.